Circumsporozoite protein (CSP) variants of P. vivax, besides having variations in the protein repetitive portion, can differ from each other in aspects such as geographical distribution, intensity of transmission, vectorial competence and immune response. Such aspects must be considered to P. vivax vaccine development. Therefore, we evaluated the immunogenicity of novel recombinant proteins corresponding to each of the three P. vivax allelic variants (VK210, VK247 and P. vivax-like) and of the C-terminal region (shared by all PvCSP variants) in naturally malaria-exposed populations of Brazilian Amazon. Our results demonstrated that PvCSP-VK210 was the major target of humoral immune response in studied population, presenting higher frequency...
Plasmodium vivax is the most common species that cause malaria outside of the African continent. The...
Plasmodium vivax is the most common species that cause malaria outside of the African continent. The...
An important step when designing a vaccine is identifying the antigens that function as targets of n...
Circumsporozoite protein (CSP) variants of P. vivax, besides having variations in the protein repeti...
The cell-traversal protein for ookinetes and sporozoites (CelTOS), a highly conserved antigen involv...
Recently, we found that a recombinant protein based on the 19 kDa C-terminal region of the Plasmodiu...
Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical climates wo...
In Brazil, Plasmodium vivax infection accounts for around 80% of malaria cases. This infection has a...
BACKGROUND: Antigenic polymorphisms are considered as one of the main strategies employed by malaria...
Background: Progress towards the development of a malaria vaccine against Plasmodium vivax, the most...
Background: Progress towards the development of a malaria vaccine against Plasmodium vivax, the most...
BACKGROUND: Progress towards the development of a malaria vaccine against Plasmodium vivax, the most...
Background: Progress towards the development of a malaria vaccine against Plasmodium vivax, the most...
In previous immuno-epidemiological studies of the naturally acquired antibody responses to merozoite...
In previous immuno-epidemiological studies of the naturally acquired antibody responses to merozoite...
Plasmodium vivax is the most common species that cause malaria outside of the African continent. The...
Plasmodium vivax is the most common species that cause malaria outside of the African continent. The...
An important step when designing a vaccine is identifying the antigens that function as targets of n...
Circumsporozoite protein (CSP) variants of P. vivax, besides having variations in the protein repeti...
The cell-traversal protein for ookinetes and sporozoites (CelTOS), a highly conserved antigen involv...
Recently, we found that a recombinant protein based on the 19 kDa C-terminal region of the Plasmodiu...
Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical climates wo...
In Brazil, Plasmodium vivax infection accounts for around 80% of malaria cases. This infection has a...
BACKGROUND: Antigenic polymorphisms are considered as one of the main strategies employed by malaria...
Background: Progress towards the development of a malaria vaccine against Plasmodium vivax, the most...
Background: Progress towards the development of a malaria vaccine against Plasmodium vivax, the most...
BACKGROUND: Progress towards the development of a malaria vaccine against Plasmodium vivax, the most...
Background: Progress towards the development of a malaria vaccine against Plasmodium vivax, the most...
In previous immuno-epidemiological studies of the naturally acquired antibody responses to merozoite...
In previous immuno-epidemiological studies of the naturally acquired antibody responses to merozoite...
Plasmodium vivax is the most common species that cause malaria outside of the African continent. The...
Plasmodium vivax is the most common species that cause malaria outside of the African continent. The...
An important step when designing a vaccine is identifying the antigens that function as targets of n...